CTTQ
Status and phase
Conditions
Treatments
About
This study is divided into two parts. Phase Ib is a randomized, double-blind, placebo-controlled trial, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, preliminary efficacy, and immunogenicity of TQA3038 injection in patients with chronic hepatitis B. It is expected to include 72 subjects. Phase IIa adopted an open-label, randomized, parallel-controlled design, with a total of 90 subjects included, mainly evaluating the changes in serum HBsAg compared to baseline at the end of the 48th week.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
162 participants in 2 patient groups
Loading...
Central trial contact
Qin Ning, Doctor; Junqi Niu, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal